CJC-1295 regulatory and compounding status in 2026
Where a much-searched growth-hormone peptide actually stands with the FDA — in plain English.
TL;DR
CJC-1295 is not FDA-approved for any use. The FDA placed it in Category 2 of its review for pharmacy compounding in 2023. FDA removed CJC-1295 from Category 2 on September 27, 2024, after its nomination was withdrawn. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list. Access stays limited and physician-gated.
What CJC-1295 regulatory status means
CJC-1295 regulatory status is best summed up in one line: not approved, and not cleared for routine compounding. CJC-1295 is a synthetic GHRH analog — a lab-made copy of growth-hormone-releasing hormone (in plain English: the body's own "make more growth hormone" signal). It has never earned FDA approval. Its standing today comes from a compounding review, not a drug-approval decision.
How the category system works
The FDA sorts substances nominated for 503A compounding into buckets. Think of it like an airport security line with three lanes. Category 1 substances may be compounded while review continues. Category 2 substances are flagged for significant safety concerns and set aside. Category 3 covers substances nominated without adequate support. CJC-1295 was in Category 2 until FDA removed it on September 27, 2024. The label is a status, not a final verdict.
Who asks about it
People search this topic after hearing about CJC-1295 for energy, recovery, or growth-hormone support. They usually ask a practical question: is CJC-1295 FDA-approved, and can I get it legally right now? The honest answer requires separating marketing buzz from the actual federal record.
What the research says
CJC-1295 has real but limited human data. An early clinical study reported that a single injection raised growth hormone and IGF-1 levels for several days in healthy adults (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). That study explored pharmacology, not long-term safety. The FDA later placed CJC-1295 in Category 2 (FDA, 2023) and removed it on September 27, 2024. Both facts can be true at once.
What to know before considering it
Regulatory status is not the same as a safety judgment for you personally. "Available from a website" is not the same as "legal and evaluated." Any legitimate access to a compounded peptide runs through a licensed prescriber and a properly licensed pharmacy, in states where that is permitted.
The Halftime POV
We track this so members do not have to parse Federal Register language themselves. Our stance is boring on purpose: follow the current rules, work only with licensed physicians, and treat gray-market shortcuts as a risk, not a hack.
Related reading:
- Who the peptide category framework affects
- Why some peptides are still Category 2
- Category 2 and patient risk
- Sermorelin's regulatory status
FAQ
Is CJC-1295 FDA-approved? No. CJC-1295 has never received FDA approval for any use. It has appeared in early clinical research, but that is not approval. Any compounded version is prepared by a pharmacy and is not itself FDA-approved.
What is CJC-1295 Category 2 status? The FDA placed CJC-1295 in Category 2 in 2023 after it flagged safety questions. FDA removed CJC-1295 from Category 2 on September 27, 2024, after its nomination was withdrawn. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list. Category 2 is a regulatory holding place, not an approval and not a statutory ban.
Can you still get CJC-1295 in 2026? Access is limited and depends on federal policy that is still moving. FDA removed CJC-1295 from Category 2 on September 27, 2024, after its nomination was withdrawn. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.
Disclaimer
Several peptides discussed in this article — including CJC-1295 — were previously in FDA's Category 2. FDA removed them from Category 2 on September 27, 2024. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
Want reliable updates as peptide rules change? Get started with Halftime Health.
Sources
- U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A." FDA, 2023. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." FDA, 2023. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Teichman SL, et al. "Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295." Journal of Clinical Endocrinology & Metabolism, 2006. PMC1435783.
Frequently asked questions
Is CJC-1295 FDA-approved?
No. CJC-1295 is not an FDA-approved drug. It has been studied in early clinical research but has never received FDA approval for any use. Any compounded version is prepared by a pharmacy and is not itself FDA-approved.
What is CJC-1295 Category 2 status?
In its review of substances nominated for 503A pharmacy compounding, the FDA placed CJC-1295 in Category 2 in 2023, meaning it flagged significant safety questions. FDA removed CJC-1295 from Category 2 on September 27, 2024, after its nomination was withdrawn. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list. Category 2 is a regulatory holding place, not an approval and not a ban by statute.
Can you still get CJC-1295 in 2026?
Access is limited and depends on evolving federal policy. FDA removed CJC-1295 from Category 2 on September 27, 2024, after its nomination was withdrawn. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. Legitimate access runs only through licensed prescribers and pharmacies operating within current rules.
Why was CJC-1295 restricted?
The FDA cited limited safety data and manufacturing questions when it sorted nominated peptides. CJC-1295 is a synthetic growth-hormone-releasing hormone analog, and regulators wanted more evidence before allowing broad compounding.
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.